Archive for November, 2011
« Previous Entries Next Entries »Cytokinetics Says Experimental Lou Gehrig’s Disease Drug Safe in Study – Bloomberg
Wednesday, November 30th, 2011
Cytokinetics Says Experimental Lou Gehrig's Disease Drug Safe in StudyBloombergThe ALS therapy, CK-2017357, caused mild dizziness in some of the 24 patients in the second of three trials typically required for US regulatory approval, the San Francisco-based company said today in a statement. Three patients saw their symptoms …Cytokinetics Announces Positive Results From Phase II [...]
Cytokinetics Reports Positive Results From Phase II Clinical Trial Of CK-2017357 – RTT News
Wednesday, November 30th, 2011Cytokinetics Reports Positive Results From Phase II Clinical Trial Of CK-2017357RTT News(RTTNews) – Cytokinetics, Inc. (CYTK: News ) announced positive results from the first cohort, or Part A, of a continuing Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis, or ALS. The company stated that CK-2017357 …Cytokinetics Announces Positive Results From [...]
Cytokinetics Announces Positive Results From Phase II Clinical Trial … – MarketWatch (press release)
Wednesday, November 30th, 2011Cytokinetics Announces Positive Results From Phase II Clinical Trial …MarketWatch (press release)The authors concluded that the ALSFRS, as it has evolved into the ALSFRS-R, continues to be a valuable tool in ALS clinical and drug development research, and has become a template for assessing functional changes in ALS patients and other patients …
Neuroprotection – Drugs, Markets and Companies – PR Newswire (press release)
Wednesday, November 30th, 2011Neuroprotection – Drugs, Markets and CompaniesPR Newswire (press release)Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as …and more »
Adeona Reports Positive Clinical Study Results Of Oral Zinc For ALS Collaborator – RTT News
Wednesday, November 30th, 2011Adeona Reports Positive Clinical Study Results Of Oral Zinc For ALS CollaboratorRTT News(RTTNews) – Adeona Pharmaceuticals, Inc. (AEN: News ) announced that its clinical collaborator for amyotrophic lateral sclerosis, or ALS, PNA Center for Neurological Research, reported top-line results from its pilot Phase I/II open label, …Positive Clinical Study Results Reported by Adeona's Oral Zinc [...]
Adeona Reports Positive Clinical Study Results Of Oral Zinc For ALS Collaborator – NASDAQ
Wednesday, November 30th, 2011Adeona Reports Positive Clinical Study Results Of Oral Zinc For ALS CollaboratorNASDAQ(RTTNews) – Adeona Pharmaceuticals, Inc. (AEN) announced that its clinical collaborator for amyotrophic lateral sclerosis, or ALS, PNA Center for Neurological Research, reported top-line results from its pilot Phase I/II open label, three month safety …Positive Clinical Study Results Reported by Adeona's Oral Zinc [...]
Adeona (AEN) Reports Encouraging Data from Zinc Therapy Phase I/II in ALS – StreetInsider.com (subscription)
Wednesday, November 30th, 2011Adeona (AEN) Reports Encouraging Data from Zinc Therapy Phase I/II in ALSStreetInsider.com (subscription)Adeona Pharmaceuticals, Inc. (AMEX: AEN), announced today that the Company's clinical collaborator for amyotrophic lateral sclerosis (ALS), PNA Center for Neurological Research (PNA), reported top-line results from its pilot Phase I/II open label, …Positive Clinical Study Results Reported by Adeona's Oral Zinc for [...]
Positive Clinical Study Results Reported by Adeona’s Oral Zinc for ALS … – MarketWatch (press release)
Wednesday, November 30th, 2011Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS …MarketWatch (press release)While non-invasive ventilation and gastrostomy tubes prolong life by 6-12 months, the average lifespan from time of symptom onset is 2-5 years. Currently, RILUTEK is the only FDA-approved drug for ALS. RILUTEK is an NMDA receptor antagonist and has …and more »
Université Laval makes ALS breakthrough – Montreal Gazette
Tuesday, November 29th, 2011Université Laval makes ALS breakthroughMontreal GazetteThey also tested whether blocking p65 activity in mice engineered to have ALS could ease some of the disease symptoms. Julien's team found that Withaferin, a compound present in medicinal plants used in India, minimized neuron cell loss in mice. …New Drug Targets Lou Gehrig's DiseaseIvanhoeall 11 news articles »
The implications of disease coexistence – Science Codex
Tuesday, November 29th, 2011The implications of disease coexistenceScience CodexThe author concludes: "There are many important clinical and research implications for ALS-FTD. Identifying FTD patients as they are just developing motor neuron problems, even before they become clinically weak, provides a window into very early motor …
« Previous Entries Next Entries »